RE: RNS17 Jul 2025 17:53
I reflected on some of my comments re Tim and it’s irrational.
This space is super complicated and lots of regulators and professional bodies involved - nothing going to happen quickly. Not to forget patent attorneys.
I also don’t want them posting comms for the sake of it, because we would slate him for that too.
Back to basics - Phase 3 trial underway, patent pending, commercial deal pending for a platform looking to revolutionise diagnostics and treatment. Mcap tiny in comparison to potential.
In essence, I thought this was good value at 3-4p so I’ll just take the enhanced value on offer today and give Tim until the end of the year.